JP2017513945A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017513945A5 JP2017513945A5 JP2017505687A JP2017505687A JP2017513945A5 JP 2017513945 A5 JP2017513945 A5 JP 2017513945A5 JP 2017505687 A JP2017505687 A JP 2017505687A JP 2017505687 A JP2017505687 A JP 2017505687A JP 2017513945 A5 JP2017513945 A5 JP 2017513945A5
- Authority
- JP
- Japan
- Prior art keywords
- medicament according
- dermal wound
- wound
- dermal
- medicament
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000003814 drug Substances 0.000 claims 8
- 230000002500 effect on skin Effects 0.000 claims 7
- 206010059512 Apoptosis Diseases 0.000 claims 2
- 230000006907 apoptotic process Effects 0.000 claims 2
- 208000002473 Lacerations Diseases 0.000 claims 1
- 206010068760 Ulcers Diseases 0.000 claims 1
- 238000005299 abrasion Methods 0.000 claims 1
- 230000001154 acute Effects 0.000 claims 1
- 230000001684 chronic Effects 0.000 claims 1
- 238000009472 formulation Methods 0.000 claims 1
- 239000000499 gel Substances 0.000 claims 1
- 238000002347 injection Methods 0.000 claims 1
- 239000007924 injection Substances 0.000 claims 1
- 239000006210 lotion Substances 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 239000002674 ointment Substances 0.000 claims 1
- 239000007921 spray Substances 0.000 claims 1
- 231100000397 ulcer Toxicity 0.000 claims 1
Claims (8)
- 有効量のＡＰＣ−３Ｋ３Ａを含み、真皮創傷に接触させる、真皮創傷を治療する医薬。
- 前記真皮創傷に局所投与される、請求項１に記載の医薬。
- ゲル、軟膏、ローション及び噴霧剤からなる群から選択される配合物の形態である、請求項１又は２に記載の医薬。
- 注射により前記真皮創傷に投与される、請求項１又は２に記載の医薬。
- 前記真皮創傷が、顕著なアポトーシスを特徴とせず、さもなければアポトーシスに起因しない、請求項１〜４のいずれか一項に記載の医薬。
- 前記真皮創傷が慢性又は急性創傷である、請求項１〜５のいずれか一項に記載の医薬。
- 前記真皮創傷が火傷、切り傷、裂傷、擦り傷、刺し傷又は潰瘍である、請求項１〜６のいずれか一項に記載の医薬。
- 前記ＡＰＣ−３Ｋ３Ａは２５０μｇ又は５００μｇの量にて提供される、請求項１〜７のいずれか一項に記載の医薬。
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU2014901397A AU2014901397A0 (en) | 2014-04-16 | Treatment of abnormal cutaneous scarring | |
| AU2014901397 | 2014-04-16 | ||
| AU2014902900A AU2014902900A0 (en) | 2014-07-25 | Use of APC analogue for wound healing | |
| AU2014902900 | 2014-07-25 | ||
| PCT/AU2015/050177 WO2015157822A1 (en) | 2014-04-16 | 2015-04-16 | Use of apc analogue for wound healing |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020031999A Division JP2020100648A (ja) | 2014-04-16 | 2020-02-27 | 創傷治癒に対するａｐｃ類似体の使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017513945A JP2017513945A (ja) | 2017-06-01 |
| JP2017513945A5 true JP2017513945A5 (ja) | 2018-05-31 |
| JP6873387B2 JP6873387B2 (ja) | 2021-05-19 |
Family
ID=54323284
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017505687A Active JP6873387B2 (ja) | 2014-04-16 | 2015-04-16 | 創傷治癒に対するａｐｃ類似体の使用 |
| JP2020031999A Withdrawn JP2020100648A (ja) | 2014-04-16 | 2020-02-27 | 創傷治癒に対するａｐｃ類似体の使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020031999A Withdrawn JP2020100648A (ja) | 2014-04-16 | 2020-02-27 | 創傷治癒に対するａｐｃ類似体の使用 |
Country Status (11)
| Country | Link |
|---|---|
| US (3) | US20170035862A1 (ja) |
| EP (1) | EP3131572B1 (ja) |
| JP (2) | JP6873387B2 (ja) |
| CN (1) | CN106488773B (ja) |
| AU (1) | AU2015246656B2 (ja) |
| CA (1) | CA2946032C (ja) |
| DK (1) | DK3131572T3 (ja) |
| ES (1) | ES2890623T3 (ja) |
| PL (1) | PL3131572T3 (ja) |
| PT (1) | PT3131572T (ja) |
| WO (1) | WO2015157822A1 (ja) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2869833B1 (en) | 2012-07-04 | 2018-04-04 | ZZ Biotech LLC. | Activated protein c for use in the treatment of inflammatory skin disorders |
| WO2015157791A1 (en) | 2014-04-16 | 2015-10-22 | The University Of Sydney | Treatment of abnormal cutaneous scarring |
| CN107619437B (zh) * | 2017-11-07 | 2019-08-13 | 昆明医科大学 | 一种皮肤创伤修复肽whpp-oa1及其提纯方法与应用 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2384099T3 (es) * | 2001-06-13 | 2012-06-29 | The University Of Sydney | Proteína C para cicatrización de heridas |
| WO2005007820A2 (en) * | 2003-07-08 | 2005-01-27 | The Scripps Research Institute | Activated protein c variants with normal cytoprotective activity but reduced anticoagulant activity |
| CA2668187A1 (en) * | 2006-10-31 | 2008-06-19 | The Scripps Research Institute | Dosing regimen of activated protein c and variants having reduced anticoagulant activity |
| EP2869833B1 (en) * | 2012-07-04 | 2018-04-04 | ZZ Biotech LLC. | Activated protein c for use in the treatment of inflammatory skin disorders |
-
2015
- 2015-04-16 WO PCT/AU2015/050177 patent/WO2015157822A1/en active Application Filing
- 2015-04-16 JP JP2017505687A patent/JP6873387B2/ja active Active
- 2015-04-16 PL PL15779573T patent/PL3131572T3/pl unknown
- 2015-04-16 DK DK15779573.3T patent/DK3131572T3/da active
- 2015-04-16 EP EP15779573.3A patent/EP3131572B1/en active Active
- 2015-04-16 ES ES15779573T patent/ES2890623T3/es active Active
- 2015-04-16 PT PT157795733T patent/PT3131572T/pt unknown
- 2015-04-16 US US15/304,433 patent/US20170035862A1/en not_active Abandoned
- 2015-04-16 CA CA2946032A patent/CA2946032C/en active Active
- 2015-04-16 CN CN201580025422.7A patent/CN106488773B/zh active Active
- 2015-04-16 AU AU2015246656A patent/AU2015246656B2/en active Active
-
2018
- 2018-02-15 US US15/897,801 patent/US20180243383A1/en not_active Abandoned
-
2019
- 2019-09-13 US US16/569,975 patent/US20200000890A1/en active Pending
-
2020
- 2020-02-27 JP JP2020031999A patent/JP2020100648A/ja not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2015009105A (es) | Composiciones en solucion solida y su uso en inflamacion cronica. | |
| CL2013001602A1 (es) | Metodo para reducir o inhibir la progresion del nivel de fatiga en pacientes con esclerosis multiple y para proporcionarles neuroproteccion que comprende administrar oralmente laquinimod o una sal del mismo; laquinimod para reducir el nivel de fatiga, mejorar el estado funcional y entregar neuroproteccion en esclerosis multiple. | |
| JP2014530840A5 (ja) | ||
| MX2015016100A (es) | Inhibidores de criopirina para prevenir y tratar la inflamacion. | |
| CL2014003503A1 (es) | Composición farmacéutica para uso intramamario que comprende un ácido fosfónico y al menos un agente antimicrobiano; y uso para el tratamiento o prevención de mastitis en mamífero no humano. | |
| DK2945642T3 (da) | Faktor 1 protein til anvendelse i behandling eller forebyggelse af sygdomme | |
| MX2015009045A (es) | Composiciones y metodos para tratar el dolor severo. | |
| NI201600070A (es) | Inhibidores tetracíclicos de autotaxina | |
| MX2016008429A (es) | Derivado de piranocromenil fenol, y composicion farmaceutica para tratar un sindrome metabolico o enfermedad inflamatoria. | |
| PH12017500615A1 (en) | Ophthalmic composition comprising cyclosporine and trehalose | |
| EA201792346A1 (ru) | ПРИМЕНЕНИЕ sGC СТИМУЛЯТОРОВ, sGC АКТИВАТОРОВ, ОТДЕЛЬНО И В КОМБИНАЦИЯХ С PDE5 ИНГИБИТОРАМИ, ДЛЯ ЛЕЧЕНИЯ ПАЛЬЦЕВИДНЫХ ЯЗВ (DU), СОПУТСТВУЮЩИХ СИСТЕМНОМУ СКЛЕРОЗУ (SSc) | |
| TN2016000229A1 (en) | Gabapentinoids and sigma receptor ligands combinations. | |
| WO2016094899A3 (en) | Treatment of hmgb1-mediated inflammation | |
| JP2017513945A5 (ja) | ||
| MX2016007682A (es) | Composicion farmaceutica que comprende ivabradina amorfa. | |
| UY35328A (es) | Tratamiento de formas progresivas de esclerosis múltiple con laquinimod | |
| WO2015195684A3 (en) | Small molecule anti-scarring agents | |
| JP2015516943A5 (ja) | ||
| WO2015082590A3 (en) | Bis-mmf derivatives | |
| JP2017513944A5 (ja) | ||
| CL2016001054A1 (es) | Compuestos para el tratamiento de diabetes y complicaciones de enfermedades derivadas de la misma | |
| HRP20161317T1 (hr) | Terapijsko sredstvo za bolest koja se bazira na inhibitornom učinku čimbenika inhibitora migracije makrofaga | |
| RU2013144837A (ru) | СПОСОБ НАНЕСЕНИЯ НА ИЗДЕЛИЯ ПОКРЫТИЯ СИСТЕМЫ Ti-Cr-Al | |
| EA201692426A1 (ru) | Комбинации зальтопрофена и миорелаксанта | |
| RU2017119625A (ru) | Способ местного лечения ожогов ii-iiia степени эритропоэтином в эксперименте |